Steroid receptors, HER2/neu and Ki-67, in endometrioid type of endometrial carcinoma: Correlation with conventional histomorphological features of prognosis-Reference-Cited by-同舟云学术

Steroid receptors, HER2/neu and Ki-67, in endometrioid type of endometrial carcinoma: Correlation with conventional histomorphological features of prognosis

Published:2010-07 Issue:4 Volume:112 Page:355-363
ISSN:0065-1281
Container-title:Acta Histochemica
language:en
Short-container-title:Acta Histochemica

Author:

Chakravarty Dimple,Gupta Nalini,Goda Jayant Shastri,Srinivasan Radhika,Patel Firuza D.,Dhaliwal Lakhbir

Publisher

Elsevier BV

Subject

Cell Biology,Histology,General Medicine

Reference41 articles.

1. Correlation between receptor status and results of treatment in endometrial carcinoma;Baı˘nazarova;Vopr Onkol,2006

2. Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease;Berchuck;Am J Obstet Gynecol,1991

3. Surgical staging in endometrial cancer: Clinico-pathological findings of a prospective study;Boronow;Obstect Gynecol,1984

4. Sex steroid receptors in endometrial cancer;Chambers;Yale J Biol Med,1988

5. Estrogen and progestin receptor levels as prognosticators for survival in endometrial cancer;Chambers;Gynecol Oncol,1988

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Analysis of the Correlation between Ki-67 Expression in Endometrial Cancer and Clinicopathological Characteristics and Prognosis of Patients;J BIOL REG HOMEOS AG;2024

2. Impact of Hormone Receptor Status and Ki-67 Expression on Disease-Free Survival in Patients Affected by High-risk Endometrial Cancer;International Journal of Gynecologic Cancer;2018-03

3. Minichromosome maintenance complex component 6 (MCM6) expression correlates with histological grade and survival in endometrioid endometrial adenocarcinoma;Virchows Archiv;2017-12-14

4. Molecular profiling of estrogen receptor α and progesterone receptor transcript variants in endometrial cancer;Steroids;2015-12

5. Targeting HER2 in ovarian and uterine cancers: Challenges and future directions;Gynecologic Oncology;2014-11